This presentation was delivered at the 2012 National Drug Trends Conference, themed 'Drugs, crime and the front line: Australasian perspective'.
- One in five Australians in treatment for opioid dependence now being treated for pharmaceutical opioid dependence
- People in treatment less likely to inject; are older and more likely to live in rural Australia than a decade ago
This research project seeks to examine the patterns and costs of Pharmaceutical Benefits Scheme-subsidised opioid use, including extra-medical use, in the Australian population.
Opioid agonist treatment is commonly initiated as a first-line treatment for individuals with pharmaceutical opioid dependence, even though much of the evidence base for the use of pharmacotherapy treatments in opioid dependence has been derived from studies conducted with primarily or exclusivel
There has been very little evaluation of the effectiveness of strategies to assist GPs to manage chronic pain patients on prescription opioids, even high-risk patients.